

**Odds ratios for breast cancer and total PCBs in relation to CYP1A1 M1 genotypes in African American and white women**

Total PCBs <sup>a</sup>	CYP1A1 M1 genotype	All participants		Premenopausal		Postmenopausal	
		Patients/ controls	OR (95% CI) <sup>b</sup>	Patients/ controls	OR (95% CI) <sup>b</sup>	Patients/ controls	OR (95% CI) <sup>b</sup>
African Americans							
<0.430	Non-M1	66/75	Referent	46/51	Referent	20/24	Referent
≥0.430	Non-M1	75/67	1.5 (0.9–2.5)	21/16	1.9 (0.9–4.2)	54/51	1.0 (0.5–2.3)
<0.430	Any M1	42/46	1.0 (0.6–1.7)	35/33	1.2 (0.6–2.2)	7/13	0.6 (0.2–1.8)
≥0.430	Any M1	59/54	1.4 (0.8–2.5)	17/14	1.7 (0.8–4.1)	42/40	1.0 (0.5–2.3)
ICR (95% CI)			0.0 (-0.9,0.9)		-0.3 (-2.2,1.6)		0.4 (-0.5,1.3)
Whites							
<0.349	Non-M1	174/133	Referent	118/83	Referent	56/50	Referent
≥0.349	Non-M1	122/148	0.7 (0.5–1.0)	38/43	0.6 (0.4–1.1)	84/105	0.8 (0.5–1.3)
<0.349	Any M1	45/44	0.8 (0.5–1.2)	29/31	0.7 (0.4–1.2)	16/13	1.1 (0.5–2.5)
≥0.349	Any M1	29/32	0.8 (0.4–1.4)	11/10	0.7 (0.3–1.9)	18/22	0.8 (0.4–1.7)
ICR (95% CI)			0.4 (-0.2,0.9)		0.5 (-0.3,1.2)		0.0 (-1.1,1.0)

<sup>a</sup>Lipid-adjusted total imputed PCBs (ng/ml).

<sup>b</sup>Odds ratios adjusted for age and sampling fractions.

Any M1, M1/M1 or M1/non-M1; CI, confidence interval; ICR, interaction contrast ratio; non-M1, non-M1/non-M1.